Reuters is reporting that PE firm Carlyle Group LP is close to acquiring Johnson & Johnson’s blood-testing unit.
The deal could be finalized within the next two weeks and worth around $4 billion.
Caryle has struck a number of significant healthcare deals over the past several years, including a $3.9 billion takeover (with Hellman & Friedman) of Pharmaceutical Product Development and a $6.3 billion acquisition of nursing home operator ManorCare, according to a New York Times report.
Carlyle Group, based in Washington, D.C., is a global asset management firm specializing in PE. It has more than $185 billion in assets under management across 122 funds and 81 fund of funds vehicles.